Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HCAQ HealthCor Catalio Acquisition	$0.73 +5.5%	$8.72	$9.48 ▼ $11.00	$15.46M	N/A	114,974 shs	140,815 shs
IMMX Immix Biopharma	$2.56 +6.0%	$2.18	$1.26 ▼ $3.00	$67.18M	0.24	151,619 shs	101,832 shs
NRXP NRx Pharmaceuticals	$3.31 -0.3%	$2.77	$1.10 ▼ $6.01	$57.40M	1.59	419,969 shs	93,865 shs
VTGN VistaGen Therapeutics	$2.03 -0.7%	$2.28	$1.90 ▼ $4.21	$59.48M	0.61	177,661 shs	107,238 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HCAQ HealthCor Catalio Acquisition	+5.48%	+1.06%	-14.69%	+4.97%	-24.85%
IMMX Immix Biopharma	+6.02%	+14.06%	+21.09%	+70.33%	+4.29%
NRXP NRx Pharmaceuticals	-0.30%	-5.43%	+21.69%	+84.92%	+28.29%
VTGN VistaGen Therapeutics	-0.74%	-1.22%	-15.27%	-13.83%	-38.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HCAQ HealthCor Catalio Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IMMX Immix Biopharma	3.3183 of 5 stars	3.5	5.0	0.0	0.0	0.6	3.3	0.6
NRXP NRx Pharmaceuticals	2.0843 of 5 stars	3.6	1.0	0.0	0.0	2.5	0.8	0.6
VTGN VistaGen Therapeutics	1.3982 of 5 stars	0.0	5.0	0.0	0.0	0.6	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HCAQ HealthCor Catalio Acquisition	0.00	N/A	N/A	N/A
IMMX Immix Biopharma	3.00	Buy	$7.00	173.97% Upside
NRXP NRx Pharmaceuticals	3.20	Buy	$28.50	761.03% Upside
VTGN VistaGen Therapeutics	3.00	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest HCAQ, VTGN, IMMX, and NRXP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
6/18/2025	VTGN VistaGen Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
6/6/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
6/4/2025	IMMX Immix Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
5/16/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
4/30/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
4/29/2025	NRXP NRx Pharmaceuticals	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $46.00

(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HCAQ HealthCor Catalio Acquisition	N/A	N/A	N/A	N/A	N/A	N/A
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	$0.48 per share	N/A
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	($1.48) per share	N/A
VTGN VistaGen Therapeutics	$490K	120.51	N/A	N/A	$2.44 per share	0.83

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HCAQ HealthCor Catalio Acquisition	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
IMMX Immix Biopharma	-$21.61M	-$0.70	N/A	N/A	N/A	N/A	-130.02%	-86.33%	8/11/2025 (Estimated)
NRXP NRx Pharmaceuticals	-$25.13M	-$2.01	N/A	N/A	N/A	N/A	N/A	-355.00%	8/13/2025 (Estimated)
VTGN VistaGen Therapeutics	-$51.42M	-$1.66	N/A	N/A	N/A	-6,777.08%	-58.88%	-52.38%	8/12/2025 (Estimated)

Latest HCAQ, VTGN, IMMX, and NRXP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
6/17/2025	Q4 2025	VTGN VistaGen Therapeutics	-$0.52	-$0.43	+$0.09	-$0.43	$0.18 million	($0.01) million
5/15/2025	Q1 2025	NRXP NRx Pharmaceuticals	-$0.40	-$0.34	+$0.06	-$0.34	$1.14 million	$1.14 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HCAQ HealthCor Catalio Acquisition	N/A	N/A	N/A	N/A	N/A
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VTGN VistaGen Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HCAQ HealthCor Catalio Acquisition	N/A	0.48	0.48
IMMX Immix Biopharma	N/A	1.80	1.80
NRXP NRx Pharmaceuticals	N/A	0.22	0.22
VTGN VistaGen Therapeutics	N/A	6.51	6.51

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HCAQ HealthCor Catalio Acquisition	84.18%
IMMX Immix Biopharma	11.26%
NRXP NRx Pharmaceuticals	4.27%
VTGN VistaGen Therapeutics	78.39%

Insider Ownership

Company	Insider Ownership
HCAQ HealthCor Catalio Acquisition	N/A
IMMX Immix Biopharma	55.40%
NRXP NRx Pharmaceuticals	19.00%
VTGN VistaGen Therapeutics	1.29%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HCAQ HealthCor Catalio Acquisition	2	21.31 million	N/A	Not Optionable
IMMX Immix Biopharma	9	27.88 million	12.43 million	Optionable
NRXP NRx Pharmaceuticals	2	17.29 million	14.00 million	Optionable
VTGN VistaGen Therapeutics	40	29.16 million	28.78 million	Optionable

HCAQ, VTGN, IMMX, and NRXP Headlines

Recent News About These Companies

Stifel Maintains Buy on Vistagen Therapeutics, Inc. (VTGN) Despite PAL-4 Delay

July 3 at 2:24 AM | msn.com

VTGN Vistagen Therapeutics, Inc. - Seeking Alpha

June 27, 2025 | seekingalpha.com

Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

June 25, 2025 | businesswire.com

Vistagen Therapeutics, Inc. (VTGN) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

William Blair Issues Negative Forecast for VTGN Earnings

June 23, 2025 | marketbeat.com

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2025 Earnings Call Transcript

June 22, 2025 | insidermonkey.com

William Blair Reaffirms Their Buy Rating on VistaGen Therapeutics (VTGN)

June 20, 2025 | theglobeandmail.com

Vistagen Therapeutics’ Earnings Call Highlights Progress and Challenges

June 19, 2025 | tipranks.com

What is William Blair's Forecast for VTGN Q1 Earnings?

June 19, 2025 | marketbeat.com

VistaGen Therapeutics (NASDAQ:VTGN) Earns "Outperform" Rating from William Blair

June 18, 2025 | marketbeat.com

Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid ...

June 18, 2025 | finance.yahoo.com

Vistagen Therapeutics Reports Progress in Clinical Trials

June 17, 2025 | tipranks.com

Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call Transcript

June 17, 2025 | seekingalpha.com

Vistagen Therapeutics (NASDAQ:VTGN) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPS

June 17, 2025 | marketbeat.com

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

June 17, 2025 | businesswire.com

Insights into VistaGen Therapeutics's Upcoming Earnings

June 16, 2025 | benzinga.com

Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Report Preview: What to Look For

June 16, 2025 | gurufocus.com

Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025

June 12, 2025 | businesswire.com

Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference

May 23, 2025 | businesswire.com

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference

April 17, 2025 | businesswire.com

Why Vistagen Therapeutics, Inc.’s (VTGN) Stock Is Down 10.10%

April 8, 2025 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCAQ, VTGN, IMMX, and NRXP Company Descriptions

HealthCor Catalio Acquisition NASDAQ:HCAQ

HealthCor Catalio Acquisition Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2020 and is based in New York, New York.

Immix Biopharma NASDAQ:IMMX

$2.56 +0.15 (+6.02%)

Closing price 07/3/2025 01:04 PM Eastern

Extended Trading

$2.56 0.00 (0.00%)

As of 07/3/2025 04:52 PM Eastern

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

NRx Pharmaceuticals NASDAQ:NRXP

$3.31 -0.01 (-0.30%)

Closing price 07/3/2025 03:44 PM Eastern

Extended Trading

$3.30 -0.01 (-0.42%)

As of 07/3/2025 04:45 PM Eastern

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

VistaGen Therapeutics NASDAQ:VTGN

$2.02 -0.02 (-0.74%)

Closing price 07/3/2025 03:33 PM Eastern

Extended Trading

$2.03 +0.00 (+0.25%)

As of 07/3/2025 04:25 PM Eastern

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time